EUROPEAN CURRICULUM VITAE

PERSONAL INFORMATION

Name	**Silvia Consalvi**
Date of Birth	
Telephone	
Address	
E-mail	silvia.consalvi17@gmail.com
Pec	silvia.consalvi@pec.enpab.it
Nationality	Italian

EDUCATION AND TRAINING

• Dates (from – to)	31/10/2018 – 31/10/2028
• Name and type of organisation providing education and training	Ministry of University and Research
• Title of qualification awarded	Qualification as Associate Professor, **06/A2 - General Pathology and Clinical Pathology.**
• Dates (from – to)	18/09/2018 – 18/09/2028
• Name and type of organisation providing education and training	Ministry of University and Research
• Title of qualification awarded	Qualification as Associate Professor, **05/F1 - Applied Biology.**
• Dates (from – to)	01/08/2018 – 01/08/2028
• Name and type of organisation providing education and training	Ministry of University and Research
• Title of qualification awarded	Qualification as Associate Professor, **05/E2 - Molecular Biology**
• Dates (from – to)	Sett. 2016 – Dic. 2016
• Name and type of organisation providing education and training	Institute for Genomic Medicine, UC San Diego, 9500 Gilman Drive #0761 La Jolla, California, USA.

• Title of qualification awarded	**Postdoc Short Training**. Title: HiC-mediated discovery of long-range interactions between genomic loci of primary muscle-derived interstitial cells.
• Dates (from – to)	2009 – 2013
• Name and type of organisation providing education and training	University of Rome Tor Vergata
• Title of qualification awarded	**Ph.D.** in Cellular and Molecular Biology. Thesis title: "Epigenetic reprogramming of fibro-adipogenic progenitors in dystrophic muscles by HDAC inhibitors".
• Dates (from – to)	17/12/2010
• Name and type of organisation providing education and training	University of Rome Tor Vergata
• Title of qualification awarded	Qualification as a **Biologist**
• Dates (from – to)	Nov 2009 – Feb 2010
• Name and type of organisation providing education and training	Sanford Burnham Medical Research Institute. 10905 Road to the Cure, La Jolla, CA 92121, USA.
• Qualifica conseguita	**Ph.D. Short Training.** Muscle Development and Regeneration Program.
• Dates (from – to)	2006 – 2009
• Name and type of organisation providing education and training	University of Rome Tor Vergata
• Title of qualification awarded	**II level Master Degree** in **Cellular and Molecular Biology**, 110/110 cum laude. Thesis title: “Pax7 expression regulation in muscle stem cells: conversion mechanism of regenerative signals in epigenetic modifications”.
• Dates (from – to)	2003 – 2006
• Name and type of organisation providing education and training	University of Rome Tor Vergata
• Title of qualification awarded	**I level Bachelor Degree** in **Cellular and Molecular Biology**, 10/110 cum laude. Thesis title: “Study of cell death in *in vitro* models of pancreatic adenocarcinoma”.

WORK EXPERIENCE

• Dates (from – to)	Nov 2022 – to date

• Name ad address of the employer	Unicamillus International Medical University in Rome, via di Sant'Alessandro 8, 00131 Rome, Italy.
• Occupation or position held	**Associate Professor**, MED/05 Clinical Pathology
• Main activities and responsibilities	Didactic activity in English at the Departmental Faculty of Medicine. Teaching: Clinical Pathology.
• Dates (from – to)	2020 – 2022
• Name ad address of the employer	Unicamillus International Medical University in Rome, via di Sant'Alessandro 8, 00131 Rome, Italy.
• Occupation or position held	**Contract Profe**
• Main activities and responsibilities	Didactic activity in English at the Departmental Faculty of Medicine. Teaching: Pharmacology.
• Dates (from – to)	2019 – 2022
• Name ad address of the employer	IRCCS Fondazione Santa Lucia, via del Fosso di Fiorano 64, 00143, Rome, Italy.
• Occupation or position held	**Researcher, Principal Investigator**
• Main activities and responsibilities	Direction and coordination of projects related to the study of Duchenne muscular dystrophy in order to identify diagnostic and therapeutic tools useful for monitoring and promoting skeletal muscle regeneration during the progression of the disease.
• Dates (from – to)	2018 – to date
• Name ad address of the employer	**Exofix Srl Start-Up,** via della Consulta 12, 00184 , Rome, Italy.
• Occupation or position held	**Member**
• Main activities and responsibilities	Developing a cell-free therapeutic strategy based on exosomes in order to promote the regenerative activity of adult stem cells for the treatment of degenerative diseases.
• Dates (from – to)	Mar 2017 – Apr 2017
• Name ad address of the employer	Atrofix S.r.l. via della Consulta 12, 00184 Rome, Italy
• Occupation or position held	**Consulent**
• Main activities and responsibilities	Screening of epigenetic drugs for the treatment of muscular dystrophies.
• Dates (from – to)	Sept 2016 – Dec 2018
• Name ad address of the employer	Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla 92037, California, USA. Development, Aging and Regeneration Program. Center for Genetic Disorders and Aging Research.
• Occupation or position held	**Visiting Researcher**
• Main activities and responsibilities	Study of the epigenetic and transcriptional profile of healthy and dystrophic muscle cells.

• Dates (from – to)	2015 – 2018
• Name ad address of the employer	IRCCS Fondazione Santa Lucia, via del Fosso di Fiorano 64, Rome, Italy, Dr. Pier Lorenzo Puri laboratory.
• Occupation or position held	**Senior Postdoc**
• Main activities and responsibilities	Preclinical studies for the treatment of muscular dystrophies. Responsible for exploratory studies to evaluate different clinical parameters in biopsy samples of children with Duchenne Muscular Dystrophy in a clinical trial for treatment with Givinostat. Study of the role of exosomes in regulating the regeneration of healthy and dystrophic muscles.
• Dates (from – to)	2013 – 2014
• Name ad address of the employer	IRCCS Fondazione Santa Lucia, via del Fosso di Fiorano 64, Rome, Italy, Daniela Palacios laboratory.
• Occupation or position held	**Postdoc**
• Main activities and responsibilities	Investigating signaling pathways involved in the regulation of muscle differentiation in healthy and dystrophic cells.
• Dates (from – to)	July 2011
• Name ad address of the employer	Italfarmaco SpA Via dei Lavoratori, 54 20092 Cinisello Balsamo, MI, Italy.
• Occupation or position held	**Consulent**
• Main activities and responsibilities	Analysis of circulating cytokines in dystrophic mdx mice treated with Givinostat.

PUBLICATIONS

1 Sturabotti E, **Consalvi S**, Tucciarone L, Macrì E, Di Lisio V, Francolini I, Minichiello C, Piozzi A, Vuotto C, Martinelli A. Synthesis of Novel Hyaluronic Acid Sulfonated Hydrogels Using Safe Reactants: A Chemical and Biological Characterization. Gels. 2022; 8(8):480.

2 **Consalvi S**[#], Tucciarone L, Macrì E, De Bardi M, Picozza M, Salvatori I, Renzini A, Valente S, Mai A, Moresi V, Puri PL. Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibro-adipogenic progenitors. EMBO Rep. 2022; 23(6):e54721. **First author**. **# Co-Corresponding author.**

3 Sandonà M, **Consalvi S***, Tucciarone L, De Bardi M, Scimeca M, Angelini D, Buffa V, D'Amico A, Bertini E, Cazzaniga S, Bettica P, Bouché M, Bongiovanni A, Puri PL, Saccone V. HDAC inhibitors tune miRNAs in extracellular vesicles of dystrophic muscle-resident mesenchymal cells. EMBO Rep. 2020; 21(9):e50863.*** Co-first author.**

4 Iannotti FA, Pagano E, Adinolfi S, Mazzarella E, Guardiola O, **Consalvi S,** Saccone V, Puri PL, Piscitelli F, Gazzerro E, Carrella E, Capasso R, Minchiotti G, Di Marzo V. Endocannabinoid CB1 receptor is a target for PAX7 in satellite cells and implicated in Duchenne Muscular Dystrophy. Nature Comm. 2018; 9(1): 3950.

5 Marroncelli N, Bianchi M, Bertin M, **Consalvi S**, Saccone V, De Bardi M, Puri PL, Palacios D, Adamo S, Moresi V. HDAC4 regulates satellite cell proliferation and differentiation by targeting P21 and Sharp1 genes. Scientific reports 2018; 8 (1): 3448.

6 Tucciarone L, Etxaniz U, Sandoná M, **Consalvi S**[#], Puri PL, Saccone V. Advanced methods to study the cross-talk between Fibro-adipogenic Progenitors and Muscle Stem Cells. Methods in Mol Biol 2018; 231-256. **# Co-Corresponding author.**

7 **Consalvi S**, Brancaccio A, Dall'Agnese A, Puri PL, Palacios D. Praja1 E3 ubiquitin ligase promotes skeletal myogenesis through degradation of EZH2 upon p38α activation. Nature Comm. 2017; 8:13956. doi: 10.1038/ ncomms13956. **First author**.

8 **Consalvi S**, Sandoná M, Saccone V. Epigenetic Reprogramming of Muscle Progenitors: Inspiration for Clinical Therapies. Stem Cells International 2016; 2016:6093601. **First author**.

9 Sandoná M, **Consalvi S**, Tucciarone L, Puri PL, Saccone V. HDAC inhibitors for muscular dystrophies: progress and prospects. Expert Opinion on Orphan Drugs 2016; 4 (2), 125-127.

10 Giordani L, Sandoná M, Rotini A, Puri PL, **Consalvi S**[#], Saccone V. Muscle-specific microRNAs as biomarkers of Duchenne Muscular Dystrophy progression and response to therapies. Rare Diseases 2014; 2 (1), e974969. **# Co-Corresponding author.**

11 **Consalvi S**, Saccone V, Mozzetta C. Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy. Epigenomics 2014**;** 6 (5), 547-560. **First author**.

12 Saccone V, **Consalvi S***, Giordani L, Mozzetta C, Barozzi I, Sandonà M, Ryan T, Rojas Munoz A, Madaro L, Fasanaro P, Borsellino G, De Bardi M, Frigè GM, Termanini A, Sun X, Rossant J, Bruneau B, Mercola M, Minucci S, Puri PL. HDAC- regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles. Genes & development 2014; 28 (8), 841-857. *** Co-first author.**

13 Marroncelli N, Noviello C, **Consalvi S**, Saccone V, Puri PL, Olson EN, Adamo S, Moresi V. HDAC4 is necessary for satellite cell differentiation and muscle regeneration. Italian Journal of Anatomy and Embryology 2014;119 (1), 126.

14 **Consalvi S,** Mozzetta C, Bettica P, Germani M, Fiorentini F, Rocchetti M, Leoni F., Modena D, Monzani V, Fossati G, Mascagni P, Puri PL, Saccone S. Preclinical studies with pharmacological treatment of murine model of Duchenne Muscular Dystrophy with the Histone Deacetylase inhibitor Givinostat. Mol Med. 2013;19:79-87. **First author**.

15 Mozzetta C, **Consalvi S***, Saccone V, Tierney M, Diamantini A, Mitchel KJ, Marazzi G, Borsellino G, Battistini L, Sassoon D, Sacco A, Puri PL. Fibroadipogenic progenitors mediate the ability of HDAC inhibitors to promote regeneration in dystrophic muscles of young, but not old mdx mice. EMBO Mol Med. 2013;5(4):626-39. *** Co-first author.**

16 **Consalvi S**, Mozzetta C, Bettica P, Mascagni P, Monzani V, Germani M, Del Bene F, Puri PL, Saccone V.TP 2 Givinostat improves histological and functional parameters in mdx mice dose and concentration dependently. Neuromuscular Disorders, 2012;22 (9), 847. **First author**.

17 Forcales SV, Albini S, Giordani L, Malecova B, Cignolo L, Chernov A, Coutinho P, Saccone V, **Consalvi S**, Williams R, Wang K, Wu Z, Baranovskaya S, Miller A, Dilworth FJ, Puri PL. Signal-dependent incorporation of MyoD-BAF60c into Brg1-based SWI/SNF chromatin-remodelling complex. EMBO J. 2012;31(2):301-16.

18 **Consalvi S**, Saccone V, Giordani L, Minetti G, Mozzetta C, Puri PL. Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases. Mol Med. 2011;17(5-6):457-65. **First author**.

19 Mozzetta C, **Consalvi S***, Saccone V, Forcales SV, Puri PL, Palacios D. Selective control of Pax7 expression by TNF- activated p38α/polycomb repressive complex 2 (PRC2) signaling during muscle satellite cell differentiation. Cell Cycle. 2011;10(2):191-8. *** Co-first author**.

20 Palacios D, Mozzetta C, **Consalvi S**, Caretti G, Saccone V, Proserpio V, Marquez VE, Valente S, Mai A, Forcales SV, Sartorelli V, Puri PL. TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell. 2010;7(4):455-69.

PATENTS

1 - Inventors:: Saccone V, Sandonà M, **Consalvi S**. Owner: Exofix Srl. Name of the Invention: Fibroadipogenic Progenitor-derived exosomes for regeneration of dystrophic muscles. Status Pending.
Country patent number, date of publication:
- EP3598978A1, 2020;
- WO2020020857A1, 2020;
- US20210268030A1, 2021;
- EP3826648A1, 2021;

2 - Inventors:: Saccone V, **Consalvi S**, Puri PL, Mascagni P. Owner: Italfarmaco SpA. Name of the invention: Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen- 2-yl- methyl]-ammonium chloride for use in the treatment of muscular dystrophy. Status Active. Country patent number, date of publication:
- CA2857082C, 2019;
- US9867799B2, 2018;
- AU2012368818B2, 2017;
- US9421184B2, 2016;

AWARDS

1 "Luigi Amadio" award for the best young Researcher at Fondazione Santa Lucia, Rome. 2018

2 Telethon award of merit for research. 2013.

3 Telethon award of merit for research. 2012.

4 Telethon award of merit for research. 2011.

5 Telethon award of merit for research. 2010.

6 "Sebastiano e Rita Raeli" award for the best graduated students of University of Rome Tor Vergata. 2009.

FELLOWSHIPS AND GRANTS

1 Ministry of Health, 5x1000 Fondazione Santa Lucia: Studio della resistenza al trattamento con Inibitori delle Istone Deacetilasi durante la progressione della Distrofia Muscolare di Duchenne. 12.000€. Role: Principal Investigator. 2021.

2 Parent Project Onlus Grant. Title: Metabolic reprogramming: a novel therapeutic strategy for Duchenne Muscular Dystrophy. 80.000€. Role: Principal Investigator. 2019 - 2021.

3 Afm Trampoline Grant. Title: Identification of the chromatin profile predicting the responsiveness of dystrophic patients to epigenetic therapy. 50.000€. Role: Principal Investigator. 2019-2021.

4 Fondazione Cariplo grant. Title: The Trithorax and Polycomb group proteins UTX and EzH2 in the Frailty Syndrome. 399.300€. Role: Collaborator. 2018 - 2021.

5 Ministry of Health, Young Researcher. Title: Regenerative potential of Fibro-Adipogenic Progenitors derived exosomes in the treatment of Duchenne Muscular Dystrophy with Histone Deacetylase Inhibitors. 450.000€. Role: Co-Principal Investigator. 2018-2022.

6 Afm French Telethon Postdoctoral fellowship. Title: Exosome-mediated HDACi/miR-143/STAT3 network in the regulation of satellite cells expansion and muscle regeneration. 51.000€. 2018 - 2019.

7 Epigen travel grant for training of young scientists in foreign laboratories at Institute for Genomic medicine, University of California, San Diego, USA. Title: HiC-mediated discovery of long-range interactions between genomic loci of primary muscle- derived interstitial cells". 6.000€. 2016.

8 Afm Trampoline Grant. Title: "Soluble mediators of the functional interactions between fibro-adipogenic progenitors and satellite cells in the pathogenesis and treatment of Duchenne Muscular Dystrophy". 50.000€. Role: Collaborator. 2015-2016.

9 Airc grant. Title: Epigenetic modifiers in rhabdomyosarcoma. 222.000€. Role: Collaborator. 2014 - 2016.

10 Telethon PhD fellowship for the study of neuromuscular diseases at University of Rome Tor Vergata. 50.000€. 2009 - 2012.